Oxaliplatin-based combined-modality therapy for rectal cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 15, 2003, Pages 26-33

  Minsky, Bruce D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; RALTITREXED; UFT;

ACUTE TOXICITY; ANUS SPHINCTER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; HIGH RISK PATIENT; HUMAN; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; RECTUM SURGERY; SIDE EFFECT; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0141993874     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00402-0     Document Type: Conference Paper

References (78)

1. National Institute of Health consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
2. Neugut AI, Fleischauer AT, Sundararajan V, et al: Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: A population-based study. J Clin Oncol 20:2643-2650, 2002
3. Gunderson LL, Sargent DJ, Tepper JE, et al: Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: A pooled analysis. Int J Radiat Oncol Biol Phys 54:386-396, 2002
4. Bosset JF, Horiot JC, Hamers HP, et al: Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol 61:7-13, 2001
5. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high risk rectal carcinoma. N Engl J Med 324:709-715, 1991
6. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
7. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 13:566-575, 2002
8. Tepper JE, O'Connell M, Niedzwiecki D, et al: Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control - Final report of intergroup 0114. J Clin Oncol 20: 1744-1750, 2002
9. Minsky BD, Cohen AM, Kemeny N, et al: Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach. J Clin Oncol 10:1218-1224, 1992
10. Sauer R, Fietkau R, Wittekind C, et al: Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 177:173-181, 2001
11. Roh MS, Petrelli N, Wieand S, et al: Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 20:123a, 2001 (abstr 490),
12. Willett CG, Badizadegan K, Ancukiewicz M, et al: Prognostic factors in stage T3N0 rectal cancer: Do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 42:167-173, 1999
13. Merchant NB, Guillem JG, Paty PB, et al: T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 3:642-647, 1999
14. Skibber JM, Hoff PM, Minsky BD: Cancer of the recturn, in Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, Williams and Wilkins, 2001, pp 1271-1318
15. Heriot AG, Grundy A, Kumar D: Preoperative staging of rectal carcinoma. Br J Surg 86:17-28, 1999
16. Kim NK, Kim MJ, Yun SH, et al: Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. Dis Colon Rectum 42:770-775, 1999
17. Guillem JG, Moore HG, Akhurst T, et al: Prospective evaluation of the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation. Proc Am Soc Clin Oncol 21:145a, 2002 (abstr 579)
18. Whiteford MH, Whiteford HM, Yee LF, et al: Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759-767; discussion 767-770, 2000
19. Minsky BD: Multidisciplinary management of tesectable rectal cancer. Oncology (Huntingt) 10:1701-1708; discussion 1714-1718, 1996
20. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980-987, 1997
21. Camma C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 284:1008-1015, 2000
22. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291-1304, 2001
23. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
24. van de Velde CJH: Preoperative radiotherapy and TME-surgery for rectal cancer: Detailed analyses in relation to quality control in a randomized trial. Proc Am Soc Clin Oncol 21: 127a, 2002 (abstr 506)
25. Marijnen CA, Kapiteijn E, van de Velde CJ, et al: Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 20:817-825, 2002
26. Hartley A, Giridharan S, Gray L, et al: Retrospective study of acute toxicity following short-course preoperative radiotherapy. Br J Surg 89:889-895, 2002
27. Nagtegaal ID, van de Velde CJ, van der Worp E, et al: Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J Clin Oncol 20:1729-1734, 2002
28. Graf W, Dahlberg M, Osman MM, et al: Short-term preoperative radiotherapy results in down-staging of rectal cancer: A study of 1316 patients. Radiother Oncol 43:133-137, 1997
29. Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, et al: No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976-1984, 2001
30. Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 17:2396-2402, 1999
31. Sauer R, Fietkau R, Martus P, et al: Adjuvant and neoadjuvant radiochemotherapy for advanced rectal cancer - First results of the German multicenter phase-III-trial. Int J Radiat Oncol Biol Phys 48:119, 2000 (abstr)
32. Wagman R, Minsky BD, Cohen AM, et al: Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: Long term follow-up. Int J Radiat Oncol Biol Phys 42:51-57, 1998
33. Rouanet P, Saint-Aubert B, Lemanski C, et al: Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: Long-term oncologic and functional results. Dis Colon Rectum 45:305-313; discussion 313-315, 2002
34. Hyams DM, Mamounas EP, Petrelli N, et al: A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: A progress report of the National Surgical Breast and Bowel Project Protocol R0-3. Dis Colon Rectum 40:131-139, 1997
35. Valentini V, Coco C, Cellini N, et al: Preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 40:1067-1075, 1998
36. Grann A, Feng C, Wong D, et al: Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 49:987-995, 2001
37. Maghfoor I, Wilkes J, Kuvshinoff B, et al: Neoadjuvant chemoradiotherapy with sphincter-sparing surgery for low lying rectal cancer. Proc Am Soc Clin Oncol 16:274a, 1997 (abstr 971)
38. Grumann MM, Noack EM, Hoffman IA, et al: Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 233:149-156, 2001
39. Kollmorgen CF, Meagher AP, Wolff BG, et al: The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 220:676-682, 1994
40. Janjan NA, Crane C, Feig BW, et al: Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24:107-112, 2001
41. Read TE, Ogunbiyi OA, Fleshman JW, et al: Neoadjuvant external beam radiation and proctectomy for adenocarcinoma of the rectum. Dis Colon Rectum 44:1778-1790, 2001
42. Hiotis SP, Weber SM, Cohen AM, et al: Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: An analysis of 488 patients. J Am Coll Surg 194:131-135; discussion 135-136, 2002
43. Ruo L, Tickoo S, Klimstra DS, et al: Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236:75-81, 2002
44. Valentini V, Coco C, Picciocchi A, et al: Does down-staging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674, 2002
45. Luna-Perez P, Segura J, Alvarado I, et al: Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 7:727-731, 2000
46. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786, 2001
47. Esposito G, Pucciarelli S, Alaggio R, et al: P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 8:311-318, 2001
48. Elsaleh H, Robbins P, Joseph D, et al: Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56:239-244, 2000
49. Kandioler D, Zwrtek R, Ludwig C, et al: TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235:493-498, 2002
50. Schwandner O, Bruch HP, Broll R: p21, p27, cyclin D1, and p53 in rectal cancer: Immunohistology with prognostic significance? Int J Colorec Dis 17:11-19, 2002
51. Adell GC, Zhang H, Evertsson S, et al: Apoptosis in rectal carcinoma: Prognosis and recurrence after preoperative radiotherapy. Cancer 91:1870-1875, 2001
52. Rodel C, Grabenbauer GG, Papadopoulos T, et al: Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52:294-303, 2002
53. Adell G, Zhang H, Jansson A, et al: Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 50:659-663, 2001
54. Barbaro B, Schulsinger A, Valentini V, et al: The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 43:1043-1047, 1999
55. Gavioli M, Bagni A, Piccagli I, et al: Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: Comparison between sonographic and histopathic changes. Dis Colon Rectum 43:1075-1083, 2000
56. Botwood N, James R, Vernon C, et al: A phase I study of "Tomudex" (raltitrexed) with radiotherapy (RT) as adjuvant treatment in patients (pt) with operable rectal cancer (ORC). Proc Am Soc Clin Oncol 17:277a, 1998 (abstr 1066)
57. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
58. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
59. Aschele C, Friso ML, Pucciarelli S, et al: A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 21:132a, 2002 (abstr 527)
60. Uzcudun AE, Batlle JF, Velasco JC, et al: Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: Results from a phase II study. Dis Colon Rectum 45:1349-1358, 2002
61. Feliu J, Cavilio J, Escribano A, et al: Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol 13:730-736, 2002
62. Valentini V, Morganti AG, Luzi S, et al: Chemoradiation with raltitrexed (Tomudex) and oxaliplatin in pre-operative treatment of stage II/III resectable rectal cancer: A dose-finding study. Proc Am Soc Clin Oncol 20:131a, 2001 (abstr 520)
63. Valentini V, Morganti AG, Gambacorta MA, et al: Raltitrexed (Tomudex) and oxaliplatin (Tomox) preliminary results of a phase II study of chemoradiation with pre-operative treatment of stage II/III resectable rectal cancer. Proc Am Soc Clin Oncol 21:151a, 2002 (abstr 603)
64. Gerard JP, Chapet O, Romestaing P, et al: Preoperative concurrent chemoradiation in locally advanced rectal cancer with 50 Gy and oxaliplatin (OXA) fluorouracil (FU), I-folinic acid (I-LV). The Lyon R0-04 Phase II trial. Int J Radiat Oncol Biol Phys 54:97, 2002 (abstr)
65. Carraro S, Roca EL, Cartelli C, et al: Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 54:397-402, 2002
66. Gerard J-P, Chapet O, Romestaing P, et al: Oxaliplatin (OXA), fluorouracil (5-FU), 1 leucovorin (1-LV) and radiotherapy (FolfoR 2) as preoperative treatment of advanced rectal cancer (ARC): The Lyon R0-04 phase II trial. Proc Am Soc Clin Oncol 21:146a, 2002 (abstr 581)
67. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al: Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc Am Soc Clin Oncol 21:146a, 2002 (abstr 580)
68. Klautke G, Kirchner R, Hopt U, et al: Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer. Proc Am Soc Clin Oncol 20:140a, 2001 (abstr 555)
69. Mehta VK, Fisher G, Cho C, et al: Phase II trial of preoperative radiotherapy, protracted venous infusion 5-fluorouracil and weekly CPT-11, followed by surgery for ultrasound staged T3/T4 rectal cancer. Proc Am Soc Clin Oncol 20:148a, 2001 (abstr 589)
70. Mitchell EP, Anne P, Fry R, et al: Combined modality therapy of locally advanced or recurrent adenocarcinoma of the rectum: Report of a phase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT). Proc Am Soc Clin Oncol 20:131a, 2001 (abstr 519)
71. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
72. Dunst J, Reese T, Frings S: Phase I study of capecitabine combined with simultaneous radiotherapy in rectal cancer. Proc Am Soc Clin Oncol 20:149a, 2001 (abstr 592)
73. Volter V, Stupp R, Matter M, et al: Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in rectal carcinoma. A phase I/II study. Proc Am Soc Clin Oncol 20:126b, 2001 (abstr 2254)
74. Reese T, Tanner J, Frings S, et al: Capecitabine combined with simultaneous radiotherapy in rectal cancer: A phase I study. Int J Radiat Oncol Biol Phys 48:120, 2000 (abstr)
75. Ngan S, Zalcberg JR, Kell A, et al: A phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer. Proc Am Soc Clin Oncol 20:149a, 2001 (abstr 591)
76. Kim JS, Cho MJ, Yoon WH, et al: Preoperative chemoradiation using capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 51:9, 2001 (abstr)
77. Dunst J, Reese T, Sutter T, et al: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983-3991, 2002
78. Blackstock AW, Hess S, Chaney S et al: Oxaliplatin: In vitro evidence of its radiation sensitizing activity - Preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45:253-254, 1999 (suppl 1)